CLEAR 2

CLEAR2: Decision Dx-Uveal Melanoma (UM) 15-Gene Expression Profile Test Clinical Impact Study

To evaluate physician recommendations regarding specialty referral, surveillance and adjuvant therapy following reults from the 15-gen expression profile test (DecisionDX-UM).  Data on investigator-recommended management plans will be collected via electronic Case Report Forms (eCRF) upon receipt of the DecisionDX-UM test result.

To determine the prognostic value of PRAME as an addition to the DecisionDx-UM prognostic test and to evaluate the relationships between PRAME and the common driver mutations in UM (BAP1, GNAQ/11, SF3B1 and EIF1AX), and assess the association with DecisionDx-UM testing, clinicopathologic features, and patient outcomes.